{"title":"Definitive chemoradiotherapy for pulmonary epithelial-myoepithelial carcinoma.","authors":"Keijiro Yamauchi, Masashi Yokoyama, Kayo Ueda, Riiko Komuta, Hidetaka Tanabe, So Takata, Takafumi Yanase, Yuki Hosono, Shingo Satoh, Naoko Morishita, Hideo Mori, Hidekazu Suzuki","doi":"10.1007/s13691-025-00779-6","DOIUrl":null,"url":null,"abstract":"<p><p>Pulmonary epithelial-myoepithelial carcinoma (P-EMC) is a rare subtype of salivary gland tumor that is generally considered a low-grade malignancy and is treated with surgical resection. Here, we report a case of P-EMC treated with definitive chemoradiotherapy. A 68-year-old man developed P-EMC with high-grade features, a Ki-67 labeling index of 60%, and rapidly progressing disease. The patient received concurrent chemoradiotherapy with carboplatin and paclitaxel, which resulted in a significant tumor size reduction. The patient is currently alive 9 months after completing chemoradiotherapy without disease recurrence. This case suggests that platinum-based chemoradiotherapy is a viable therapeutic option for locally advanced, unresectable P-EMCs.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"344-349"},"PeriodicalIF":0.5000,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229430/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-025-00779-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Pulmonary epithelial-myoepithelial carcinoma (P-EMC) is a rare subtype of salivary gland tumor that is generally considered a low-grade malignancy and is treated with surgical resection. Here, we report a case of P-EMC treated with definitive chemoradiotherapy. A 68-year-old man developed P-EMC with high-grade features, a Ki-67 labeling index of 60%, and rapidly progressing disease. The patient received concurrent chemoradiotherapy with carboplatin and paclitaxel, which resulted in a significant tumor size reduction. The patient is currently alive 9 months after completing chemoradiotherapy without disease recurrence. This case suggests that platinum-based chemoradiotherapy is a viable therapeutic option for locally advanced, unresectable P-EMCs.
期刊介绍：
This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO).
- Presents an online-only collection of original case reports on all types of cancer
- In particular, welcomes molecularly analyzed cancer cases
- The Official Publication of the Japan Society of Clinical Oncology (JSCO)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
